News About: Pharm. Affairs
Attraction of gigantic drug store ‘Boots’ may lead boycott against Shinsegae
The Korean Pharmaceutical Association(KPA) expressed concerns about attract a U.K. drug store Boots in Korea.
With a written statement on the 12th, the KPA showed a serious concern about the entry of the top drug st...
Will Sovaldi & Harvoni’s super-low distribution margins be addressed this year?
Gilead has attracted attention of the pharmaceutical distribution industry as planning to review the problem in distribution margins of ‘Sovaldi’ and ‘Harvoni,’ chronic hepatitis C treatments, which have super-low mar...
Multinational pharmas launched 27 new drugs this year
This year, multinational pharmaceutical companies have launched new drugs in various fields.
According to major multinational pharmaceutical companies’ status and plans on commercialization of new drugs, they have sh...
Huons to challenge to next-generation anticoagulant ‘Pradaxa’ for first time
Huons will challenge to development of Pradaxa generics for the first time among other domestic pharmaceutical companies.
According to the Ministry of Food and Drug Safety(MFDS), Huons acquired approval for a bioequi...
OTC usage rate was higher than ETC in this 1st half
In the first half of the year, OTC drugs were more used than ETC drugs.
According to the drug usage reported to the Health Insurance Review & Assessment Service, the usage of ETC drugs was increased by 4.0% from KRW ...
Drinkable arthritis agents to need more time to settle in market
It seems the ‘drinkable arthritis treatment’ which recently landed in Korea needs more time to settle in the market. Its sales were only less than KRW 500 million in the first half of the year.
According to the pharm...
Hepatitis B treatment, Baraclude’s drug price cut from the 7th
From the 7th, the upper health insurance benefit of the BMS Pharmaceutical Korea’s(CEO Hye-sun Park) chronic hepatitis B treatment, Baraclude(generic name: entecavir), will be lowered to 53.55% of the original price b...
Active process to nullify rapidly-grown ‘Eiliquis’ & ‘Pradaxa’ patents
Domestic pharmaceutical companies will challenge the patent wall of novel oral anticoagulants(NOACs), ‘Pradaxa’ and ‘Eliquis.’ They are also trying to nullify the ‘Brilinta’ patent as well.
According to the pharmaceu...
2nd golden age in insulin market with ‘Toujeo & Tresiba’
Difficulties as an injection and side effects such as hypoglycemia and weight increase…
The basal insulin market which used be considered as headache only 1-2 years ago is having the second golden age with Toujeo and...
Competition to preoccupy Viread generic market of KRW 150 billion
It’s Viread for now. After Baraclude generics, domestic pharmaceutical companies are directly aiming for Viread whose substance patent is expiring soon on November next year.
Viread is a product which become the larg...
